AdminMed

🚀 New Scientific Publication Validates AdminPatch® Microneedle Technology for Enhanced Migraine Treatment

We're excited to announce a new peer-reviewed publication featuring AdminMed's AdminPatch® microneedle arrays in the book "Technological Innovation in Pharmaceutical Research Vol. 1." The chapter, titled "Microneedle Aided Transdermal Delivery of Antimigraine Drugs," presents groundbreaking research demonstrating how our technology can revolutionize migraine treatment. This study was conducted by researchers from KVSR Siddhartha College of Pharmaceutical Sciences (Vijayawada, India) and BITS-Pilani Hyderabad Campus, with support from DST, Ministry of Science and Technology (Govt. of India) and the British Council, London, UK.

Key Quantitative Benefits Demonstrated:
✅ Up to 7.5-fold Enhancement: AdminPatch 1500 achieved remarkable increases in drug permeation - up to 7.5x for Rizatriptan and 3x for Zolmitriptan compared to passive delivery
✅ Faster Relief: Dramatically reduced lag time from ~20 hours to just 4.17 hours for Rizatriptan delivery, enabling much faster therapeutic onset for migraine sufferers
✅ Precision Engineering: Our arrays demonstrated controlled pe*******on depths from 180μm (AdminPatch 600) to 470μm (AdminPatch 1500), with perfect linear correlation (R² = 0.99)
✅ Enhanced Drug Delivery: Achieved 5-fold increase in steady-state drug flux, ensuring consistent and effective medication delivery
✅ 100% Pe*******on Efficiency: All AdminPatch arrays successfully created microconduits with simple manual application

Why This Matters for Migraine Patients: Current oral migraine medications suffer from poor bioavailability (

AdminMed The World Economic Forum and Scientific American magazine recognize microneedle technology as one of the top 10 emerging technologies! https://www.weforum.org/agenda/2020/11/2020-top-10-emerging-technologies/

🔬 New Publication Validates AdminPatch® 1200 for Revolutionary Glucose Monitoring Technology

We are excited to announce a groundbreaking publication from Nanyang Technological University Singapore demonstrating that our AdminPatch® 1200 stainless steel microneedle arrays enable minimally invasive, real-time glucose monitoring through advanced Surface Enhanced Raman Spectroscopy (SERS) technology.

Published in the Proceedings of SPIE, the research by Liu et al. from the School of Chemical and Biomedical Engineering and the School of Biological Sciences at Nanyang Technological University showcases the remarkable capabilities of our microneedle technology for intradermal measurements without drawing blood.

Key Performance Metrics Achieved with AdminPatch® 1200:

✅ Clinical-grade accuracy - RMSE of 3.3 mM for glucose prediction, approaching the clinically desirable 1 mM standard,

✅ Comprehensive measurement range - Successfully monitors glucose from 2.8-72.2 mM (hypoglycemia to severe diabetes),

✅ Minimally invasive depth - Enables measurements at 675 µm below skin surface,

✅ Low power operation - Requires only 5 mW laser power for safe in vivo use,

✅ Rapid results - 10-second measurement time for near real-time monitoring,

✅ Meets ISO/DIS 15197 standards - Achieves international clinical requirements for glucose sensors.

This research demonstrates that our robust AdminPatch® 1200 stainless steel microneedle arrays, when silver-coated, deliver glucose concentration predictions with RMSE values of 3.3 mM - performance comparable to the gold standard while eliminating the need for painful blood draws.

The future of diabetes management is here - minimally invasive, continuous, and accurate.

Read the complete publication: "Surface Enhanced Raman Spectroscopy for Malaria Diagnosis and Intradermal Measurements"
https://www.adminmed.com/files/web/publications/2018-Surface-enhanced-Raman-spectroscopy-for-intradermal-glucose-measurements-Liu.pdf

www.adminmed.com

🔬 Groundbreaking Research: AdminPen™ Enables First-Ever Intradermal Delivery of Novel Psoriasis Treatment
We're thrilled to announce a landmark publication in the European Journal of Pharmaceutics and Biopharmaceutics featuring our AdminPen™ 1200 hollow microneedle array technology!
Researchers from Harvard Medical School, Damanhour University, and Cairo University have achieved a world first: the successful intradermal delivery of teriflunomide-loaded emulsomes (TER-EMLs) for the management of psoriasis using hollow microneedle arrays. This pioneering study by Zewail et al. (2025) demonstrates the transformative potential of our AdminPen™ technology in revolutionizing psoriasis treatment.
Key Quantitative Benefits of AdminPen™ 1200 hollow microneedle array injection devices demonstrated:
✅ 100% pe*******on efficiency - All 43 hollow microneedles achieved complete skin pe*******on, creating corresponding dermal micropores for reliable drug delivery,
✅ Optimal 1100-1200 μm pe*******on depth - Effectively breaches stratum corneum and epidermis layers for direct intradermal therapeutic delivery,
✅ Superior inflammatory control - Achieved near-normal NF-KB levels (1.03 vs 0.95 ng/g in controls) compared to 4.8-fold increase in untreated psoriatic tissue,
✅ 3.5-fold antioxidant preservation - Maintained GSH levels at 4.7 pg/g tissue versus only 1.34 pg/g in positive controls
✅ Minimally invasive design - 1200 μm needle height with off-centered hollow pores ensures painless pe*******on and continuous drug flow.
This research validates AdminPen™ hollow microneedle array injection device as an enabling platform for next-generation dermatological therapeutics, offering patients a minimally invasive alternative to conventional psoriasis treatments with enhanced efficacy and reduced side effects.
Read the full paper:https://www.adminmed.com/files/web/publications/2025-Intradermal-delivery-of-teriflunomide-loaded-emulsomes-using-hollow-microneedles-Zewail.pdf
hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

www.adminmed.com

🚀 Breakthrough Research: AdminPen™ 1200 Revolutionizes Psoriasis Treatment Through Advanced Hollow Microneedle Array Injection Technology! 🚀
We're proud to share that our AdminPen™ 1200 hollow microneedle array injection devices have been featured in groundbreaking research published in the Journal of Drug Targeting, demonstrating exceptional performance in photodynamic therapy for the treatment of psoriasis.
Researchers from Damanhour University in Egypt and Cairo University successfully utilized our AdminPen™ 1200 hollow microneedle array injection technology to deliver hypericin-loaded nanocarriers for the non-invasive management of psoriasis, achieving remarkable therapeutic outcomes.
Outstanding Performance Metrics of AdminPen™ 1200:
✅ 100% Puncture Success Rate - All 43 hollow microneedles successfully created microchannels in human skin, ensuring reliable and consistent drug delivery,
📊 1480 μm Deep Drug Distribution - Achieved nearly 2X deeper drug pe*******on compared to conventional methods (750 μm), enabling therapeutic agents to reach critical skin layers,
🎯 43 High-Density Microneedles in 1 cm² - Optimal array configuration provides comprehensive coverage for efficient intradermal delivery across treatment sites,
📏 1200 μm Precision-Engineered Needles - Ideal length successfully bypasses skin barriers while enabling enhanced drug distribution beyond insertion depth,
💊 Superior Clinical Outcomes - Achieved 4.48-fold reduction in inflammatory markers and normalized antioxidant levels comparable to healthy controls when combined with photodynamic therapy
This research validates AdminPen™ 1200 as a game-changing platform for targeted dermal drug delivery, offering painless, efficient, and highly effective treatment options for challenging skin conditions.
The future of minimally invasive therapeutic delivery is here! 💉✨
📄 Read the full paper: "Combined photodynamic therapy and hollow microneedle approach for effective non-invasive delivery of hypericin" - Journal of Drug Targeting, 2024https://www.adminmed.com/files/web/publications/2024-Combined-photodynamic-therapy-and-hollow-microneedles-Abbas.pdf

www.adminmed.com